Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by research analysts at Wolfe Research to a "strong-buy" rating in a report released on Thursday,Zacks.com reports.

Several other research firms also recently weighed in on REGN. Cantor Fitzgerald reiterated a "neutral" rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Evercore ISI dropped their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Oppenheimer dropped their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Finally, TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.3 %

Shares of NASDAQ REGN traded down $25.70 during midday trading on Thursday, reaching $756.81. 1,374,549 shares of the stock were exchanged, compared to its average volume of 530,457. The company has a 50 day simple moving average of $985.21 and a 200 day simple moving average of $1,032.97. The stock has a market capitalization of $83.17 billion, a P/E ratio of 18.73, a PEG ratio of 3.04 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals has a twelve month low of $753.69 and a twelve month high of $1,211.20.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the period. Capital International Investors increased its stake in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock worth $3,011,640,000 after acquiring an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock worth $868,757,000 after acquiring an additional 184,561 shares during the period. International Assets Investment Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after acquiring an additional 879,916 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock worth $707,759,000 after acquiring an additional 11,499 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.